Our Work
Latham Advises Ipsen on Its €500 Million Inaugural Rated Notes Issuance
March 25, 2025
A Paris-based team represented the biopharmaceutical company on the issuance.
Latham & Watkins advised Ipsen, a global specialty care biopharmaceutical company, in connection with its inaugural rated notes issuance. Ipsen raised €500 million maturing in March 2032 with an annual coupon of 3.875%. The notes are admitted to trading on the regulated market of Euronext Paris.
Ipsen also renewed its €1.5 billion syndicated revolving credit facility.
Latham advised Ipsen with a capital markets team led by partner Roberto Reyes Gaskin, with associate Hana Ladhari, a banking team led by of counsel Etienne Gentil with associate Bruna Neiva Cardante, and a tax team led by partner Olivia Rauch-Ravisé, with associate Clémence Morel.